In most hospitals, newborn babies are screened for a variety of metabolic disorders, including medium-chain acyl-CoA dehydrogenase deficiency (MCADD). This screening process uses high-performance liquid chromatography (HPLC) to determine the acylcarnitine profile in the bloodstream. In newborns with MCADD, which acylcarnitine is elevated?

The acylcarnitine that is elevated in newborns with MCADD is C10.

Explanation:

MCADD (medium-chain acyl-CoA dehydrogenase deficiency) is a rare genetic disease that is given by a poor breaking of fat molecules, which leads to less energy and a build-up of substances that can be harmful to one's body.

A baby with MCADD often feels drowsy and sleepy, vomits and has seizures.

Kids with this disorder have to eat frequently and take special high sugar drinks.